neurostar.com - יחס שווי חברה להכנסות STIM

Neuronetics, Inc. (STIM) growth relies on the expansion of NeuroStar systems and an increase in insurance reimbursements. The enterprise value-to-revenue ratio visualizes the market consensus, where 1004.44 represents the latest level. However, high promotion costs and pressure from the pharmaceutical sector limit profitability. Meanwhile, its independence from macroeconomic trends transforms the asset into a reliable defensive solution during recessionary periods.
STIM (NeuroStar): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For non-invasive neurostimulation developer Neuronetics, Inc. (STIM), the EV/Sales history reflects the market valuation of its depression treatment technology potential. This metric compares the total enterprise value, adjusted for net debt, against annual sales volume. Such an approach eliminates the impact of leverage, revealing the actual value of operating assets. Amid tight Fed policy, a declining ratio signals multiple compression. This helps investors assess whether they are overpaying for innovation.